Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0W6AF
|
||||
| Former ID |
DIB010175
|
||||
| Drug Name |
YM-264
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Septic shock [ICD9: 785.52; ICD10:A41.9] | Phase 2 | [1] | ||
| Company |
Yamanouchi Pharmaceutical Co Ltd
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C28H36N4O5S
|
||||
| Canonical SMILES |
C1(NC(SC1)c1cnccc1)C(=O)N1CCN(CCC(c2ccccc2)(C)C)CC1.C(=<br />O)(/C=C/C(=O)O)O
|
||||
| CAS Number |
CAS 131888-54-5
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Platelet-activating factor receptor | Target Info | Antagonist | [2] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Staphylococcus aureus infection | |||||
| NetPath Pathway | IL5 Signaling Pathway | ||||
| Leptin Signaling Pathway | |||||
| Reactome | Class A/1 (Rhodopsin-like receptors) | ||||
| G alpha (q) signalling events | |||||
| Interferon gamma signaling | |||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| Small Ligand GPCRs | |||||
| Interferon gamma signaling | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Current Pharmaceutical Design. Page(175). | ||||
| REF 2 | Effects of YM264, a novel PAF antagonist, on puromycin aminonucleoside-induced nephropathy in the rat. Biochem Biophys Res Commun. 1991 Apr 30;176(2):781-5. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.